Anjela Tzontcheva

943 total citations · 1 hit paper
29 papers, 677 citations indexed

About

Anjela Tzontcheva is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Rheumatology. According to data from OpenAlex, Anjela Tzontcheva has authored 29 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 8 papers in Rheumatology. Recurrent topics in Anjela Tzontcheva's work include Respiratory and Cough-Related Research (12 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Voice and Speech Disorders (7 papers). Anjela Tzontcheva is often cited by papers focused on Respiratory and Cough-Related Research (12 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Voice and Speech Disorders (7 papers). Anjela Tzontcheva collaborates with scholars based in United States, United Kingdom and Canada. Anjela Tzontcheva's co-authors include Susan Huyck, John A. Smith, Carmen La Rosa, Surinder S. Birring, Alyn H. Morice, Peter V. Dicpinigaitis, Ian Pavord, Allison Martin Nguyen, Sean Curtis and Lorcan McGarvey and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Neurology.

In The Last Decade

Anjela Tzontcheva

29 papers receiving 663 citations

Hit Papers

Efficacy and safety of gefapixant, a P2X3 receptor antago... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
    2022 178 citations Lorcan McGarvey, Surinder S. Birring et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anjela Tzontcheva United States 11 218 183 171 166 107 29 677
A. Wright United States 13 150 0.7× 176 1.0× 174 1.0× 358 2.2× 86 0.8× 31 909
Yoshinari Nakatsuka Japan 19 334 1.5× 64 0.3× 118 0.7× 126 0.8× 48 0.4× 50 924
Helle Glud Binderup Denmark 13 49 0.2× 43 0.2× 193 1.1× 115 0.7× 42 0.4× 15 493
Francesca Crosti Italy 14 52 0.2× 90 0.5× 67 0.4× 48 0.3× 73 0.7× 40 884
U. Häuser Germany 12 152 0.7× 44 0.2× 284 1.7× 73 0.4× 193 1.8× 26 826
Joseph E. Robertson United States 15 98 0.4× 54 0.3× 25 0.1× 93 0.6× 59 0.6× 27 1.1k
Suhail Aamar Israel 16 46 0.2× 168 0.9× 160 0.9× 194 1.2× 56 0.5× 27 786
Inga Peters Germany 19 535 2.5× 63 0.3× 81 0.5× 65 0.4× 115 1.1× 59 1.1k
Shunichi Matsumoto Japan 19 162 0.7× 51 0.3× 70 0.4× 35 0.2× 163 1.5× 83 1.1k
Soo Yoon Kim South Korea 12 428 2.0× 36 0.2× 20 0.1× 33 0.2× 35 0.3× 18 672

Countries citing papers authored by Anjela Tzontcheva

Since Specialization
Citations

This map shows the geographic impact of Anjela Tzontcheva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjela Tzontcheva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjela Tzontcheva more than expected).

Fields of papers citing papers by Anjela Tzontcheva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjela Tzontcheva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjela Tzontcheva. The network helps show where Anjela Tzontcheva may publish in the future.

Co-authorship network of co-authors of Anjela Tzontcheva

This figure shows the co-authorship network connecting the top 25 collaborators of Anjela Tzontcheva. A scholar is included among the top collaborators of Anjela Tzontcheva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjela Tzontcheva. Anjela Tzontcheva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stanislav, Marina, Anjela Tzontcheva, Ruji Yao, et al.. (2023). Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK). Lara D. Veeken. 62(11). 3601–3609. 8 indexed citations
2.
McGarvey, Lorcan, Surinder S. Birring, Alyn H. Morice, et al.. (2022). Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. The Lancet. 399(10328). 909–923. 178 indexed citations breakdown →
3.
Dicpinigaitis, Peter V., Surinder S. Birring, Michael S. Blaiss, et al.. (2022). Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Annals of Allergy Asthma & Immunology. 130(1). 60–66. 16 indexed citations
4.
Smith, John A., Michael M. Kitt, Alan Bell, et al.. (2022). Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial. Pulmonary Therapy. 8(3). 297–310. 5 indexed citations
5.
Heijde, Désirée van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2021). Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. Lara D. Veeken. 61(2). 617–627. 3 indexed citations
6.
Dicpinigaitis, Peter V., Surinder S. Birring, Lorcan McGarvey, et al.. (2021). Comorbid Conditions and Medical History Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Clinical Trials (COUGH-1 and COUGH-2). Journal of Allergy and Clinical Immunology. 147(2). AB61–AB61. 1 indexed citations
7.
Dicpinigaitis, Peter V., Surinder S. Birring, Alyn H. Morice, et al.. (2021). Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant. OA1588–OA1588. 1 indexed citations
8.
Birring, Surinder S., Peter V. Dicpinigaitis, Lorcan McGarvey, et al.. (2021). Baseline Cough Severity and Quality of Life in Patients with Chronic Cough Participating in Two Global Phase 3 Randomized Controlled Clinical Trials. A2359–A2359. 1 indexed citations
9.
Birring, Surinder S., AH Morice, John A. Smith, et al.. (2021). Responder Analyses for Patient-Reported Outcomes in a Pooled Analysis of Two Phase III Randomized Placebo Controlled Trials of Gefapixant, a P2X3 Receptor Antagonist for the Treatment of Chronic Cough. Research Portal (Queen's University Belfast). A2354–A2354. 1 indexed citations
10.
Khalilieh, Sauzanne, et al.. (2018). Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. Basic & Clinical Pharmacology & Toxicology. 123(3). 294–300. 30 indexed citations
11.
Nieschlag, Eberhard, Pierre-Marc Bouloux, Barbara J. Stegmann, et al.. (2017). An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reproductive Biology and Endocrinology. 15(1). 17–17. 27 indexed citations
12.
Heijde, D. van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2016). LONG-TERM EFFICACY AND TOLERABILITY OF GOLIMUMAB IN ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS : RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY. Clinical and Experimental Rheumatology. 34(4). 752–752. 1 indexed citations
13.
Heijde, D. van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2016). SAT0388 Long-Term Efficacy and Tolerability of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results of The Open-Label Extension of A Randomized, Double-Blind Study. Annals of the Rheumatic Diseases. 75. 808–809. 2 indexed citations
14.
Hastrup, Nina, Sauzanne Khalilieh, David C. Dale, et al.. (2015). The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects. Cytokine. 72(2). 197–203. 12 indexed citations
15.
Sieper, Joachim, Désirée van der Heijde, Maxime Dougados, et al.. (2015). A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology. 67(10). 2702–2712. 160 indexed citations
16.
Dougados, Maxime, G. Bergman, Walter P. Maksymowych, et al.. (2015). THU0218 Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis. Annals of the Rheumatic Diseases. 74. 275–275. 3 indexed citations
17.
Stocchi, Fabrizio, Olivier Rascol, Robert A. Hauser, et al.. (2014). Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004). Neurology. 82(10_supplement). 4 indexed citations
18.
Zhang, Da, Monica Mita, Geoffrey I. Shapiro, et al.. (2012). Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 70(6). 891–898. 23 indexed citations
19.
Nottage, Michelle, Karen Kopciuk, Anjela Tzontcheva, et al.. (2006). Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study. Breast Cancer Research. 8(4). R44–R44. 30 indexed citations
20.
Briollais, Laurent, Anjela Tzontcheva, & Shelley B. Bull. (2003). Multilevel modeling for the analysis of longitudinal blood pressure data in the Framingham Heart Study pedigrees. BMC Genetics. 4(S1). S19–S19. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Wright Breakdown of academic impact, for papers by Yoshinari Nakatsuka Breakdown of academic impact, for papers by Helle Glud Binderup Breakdown of academic impact, for papers by Francesca Crosti Breakdown of academic impact, for papers by U. Häuser Breakdown of academic impact, for papers by Joseph E. Robertson Breakdown of academic impact, for papers by Suhail Aamar Breakdown of academic impact, for papers by Inga Peters Breakdown of academic impact, for papers by Shunichi Matsumoto Breakdown of academic impact, for papers by Soo Yoon Kim
Rankless by CCL
2026